<?xml version='1.0' encoding='utf-8'?>
<document id="16638740"><sentence text="Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers."><entity charOffset="0-9" id="DDI-PubMed.16638740.s1.e0" text="Ritonavir" /><entity charOffset="84-93" id="DDI-PubMed.16638740.s1.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.16638740.s1.e0" e2="DDI-PubMed.16638740.s1.e0" /><pair ddi="false" e1="DDI-PubMed.16638740.s1.e0" e2="DDI-PubMed.16638740.s1.e1" /></sentence><sentence text="A drug-drug interaction study was conducted to determine whether ritonavir (200 mg; 4 doses over 2 days) alters the pharmacokinetic disposition of bupropion (75 mg; once) coadministered to 7 healthy volunteers in a placebo-controlled 2-way crossover study"><entity charOffset="65-74" id="DDI-PubMed.16638740.s2.e0" text="ritonavir" /><entity charOffset="147-156" id="DDI-PubMed.16638740.s2.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.16638740.s2.e0" e2="DDI-PubMed.16638740.s2.e0" /><pair ddi="false" e1="DDI-PubMed.16638740.s2.e0" e2="DDI-PubMed.16638740.s2.e1" /></sentence><sentence text=" Serum samples collected from 0 to 24 hours after bupropion administration were assayed for concentrations of bupropion and metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion)"><entity charOffset="50-59" id="DDI-PubMed.16638740.s3.e0" text="bupropion" /><entity charOffset="110-119" id="DDI-PubMed.16638740.s3.e1" text="bupropion" /><entity charOffset="137-153" id="DDI-PubMed.16638740.s3.e2" text="hydroxybupropion" /><entity charOffset="155-174" id="DDI-PubMed.16638740.s3.e3" text="threohydrobupropion" /><entity charOffset="180-201" id="DDI-PubMed.16638740.s3.e4" text="erythrohydrobupropion" /><pair ddi="false" e1="DDI-PubMed.16638740.s3.e0" e2="DDI-PubMed.16638740.s3.e0" /><pair ddi="false" e1="DDI-PubMed.16638740.s3.e0" e2="DDI-PubMed.16638740.s3.e1" /><pair ddi="false" e1="DDI-PubMed.16638740.s3.e0" e2="DDI-PubMed.16638740.s3.e2" /><pair ddi="false" e1="DDI-PubMed.16638740.s3.e0" e2="DDI-PubMed.16638740.s3.e3" /><pair ddi="false" e1="DDI-PubMed.16638740.s3.e0" e2="DDI-PubMed.16638740.s3.e4" /><pair ddi="false" e1="DDI-PubMed.16638740.s3.e1" e2="DDI-PubMed.16638740.s3.e1" /><pair ddi="false" e1="DDI-PubMed.16638740.s3.e1" e2="DDI-PubMed.16638740.s3.e2" /><pair ddi="false" e1="DDI-PubMed.16638740.s3.e1" e2="DDI-PubMed.16638740.s3.e3" /><pair ddi="false" e1="DDI-PubMed.16638740.s3.e1" e2="DDI-PubMed.16638740.s3.e4" /><pair ddi="false" e1="DDI-PubMed.16638740.s3.e2" e2="DDI-PubMed.16638740.s3.e2" /><pair ddi="false" e1="DDI-PubMed.16638740.s3.e2" e2="DDI-PubMed.16638740.s3.e3" /><pair ddi="false" e1="DDI-PubMed.16638740.s3.e2" e2="DDI-PubMed.16638740.s3.e4" /><pair ddi="false" e1="DDI-PubMed.16638740.s3.e3" e2="DDI-PubMed.16638740.s3.e3" /><pair ddi="false" e1="DDI-PubMed.16638740.s3.e3" e2="DDI-PubMed.16638740.s3.e4" /></sentence><sentence text=" Derived pharmacokinetic parameters were compared between placebo/bupropion and ritonavir/bupropion trials by paired t test"><entity charOffset="66-75" id="DDI-PubMed.16638740.s4.e0" text="bupropion" /><entity charOffset="80-89" id="DDI-PubMed.16638740.s4.e1" text="ritonavir" /><entity charOffset="90-99" id="DDI-PubMed.16638740.s4.e2" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.16638740.s4.e0" e2="DDI-PubMed.16638740.s4.e0" /><pair ddi="false" e1="DDI-PubMed.16638740.s4.e0" e2="DDI-PubMed.16638740.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16638740.s4.e0" e2="DDI-PubMed.16638740.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16638740.s4.e1" e2="DDI-PubMed.16638740.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16638740.s4.e1" e2="DDI-PubMed.16638740.s4.e2" /></sentence><sentence text=" The effect of ritonavir on most pharmacokinetic parameters was minimal (&lt;20% mean change)"><entity charOffset="15-24" id="DDI-PubMed.16638740.s5.e0" text="ritonavir" /></sentence><sentence text=" The only parameters that showed a statistically significant effect were threohydrobupropion area under the blood concentration curve (14% +/- 5% decrease, mean +/- SE; P = " /><sentence text="04) and erythrohydrobupropion time-to-maximal serum concentration (161% +/- 92% increase, P = "><entity charOffset="8-29" id="DDI-PubMed.16638740.s7.e0" text="erythrohydrobupropion" /></sentence><sentence text="03), suggesting that ritonavir may inhibit the carbonyl reductase enzyme responsible for formation of these metabolites"><entity charOffset="21-30" id="DDI-PubMed.16638740.s8.e0" text="ritonavir" /><entity charOffset="47-55" id="DDI-PubMed.16638740.s8.e1" text="carbonyl" /><pair ddi="false" e1="DDI-PubMed.16638740.s8.e0" e2="DDI-PubMed.16638740.s8.e0" /><pair ddi="false" e1="DDI-PubMed.16638740.s8.e0" e2="DDI-PubMed.16638740.s8.e1" /></sentence><sentence text=" These findings indicate that short-term ritonavir dosing has only minimal impact on the pharmacokinetic disposition of a single dose of bupropion in healthy volunteers"><entity charOffset="41-50" id="DDI-PubMed.16638740.s9.e0" text="ritonavir" /><entity charOffset="137-146" id="DDI-PubMed.16638740.s9.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.16638740.s9.e0" e2="DDI-PubMed.16638740.s9.e0" /><pair ddi="false" e1="DDI-PubMed.16638740.s9.e0" e2="DDI-PubMed.16638740.s9.e1" /></sentence><sentence text="" /></document>